// App-Quantinova.ai

: Chidamide-Containing Conditioning Allogenic Hematopoietic Stem Cell Transplantation Improves Prognosis of Acute Lymphoblastic Leukemia with Pre-Transplant Response Less Than Complete Remission

Researchers

Presenter

  • Jie Ji

Principal Investigators

  • Tian Dong

  • Pu Kuang

  • Zhigang Liu

  • Jiazhuo Liu

  • Li Zhang

  • Ting Niu

  • Ting Liu

Medical Centers

  • State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

  • State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

  • Department of oncology, West China Hospital, Sichuan University, Sichuan, P.R. China, Chengdu, China

  • West China Hospital of Sichua University, Chengdu, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Cyclosporine eent

  • fludarabine tablet

  • Cytarabine liposomal

  • Chidamide

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved